{"doc_id": "33631065", "type of study": "Therapy", "title": "", "abstract": "Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19.\nThe efficacy of interleukin-6 receptor antagonists in critically ill patients with coronavirus disease 2019 (Covid-19) is unclear.\nWe evaluated tocilizumab and sarilumab in an ongoing international, multifactorial, adaptive platform trial.\nAdult patients with Covid-19, within 24 hours after starting organ support in the intensive care unit (ICU), were randomly assigned to receive tocilizumab (8 mg per kilogram of body weight), sarilumab (400 mg), or standard care (control).\nThe primary outcome was respiratory and cardiovascular organ support-free days, on an ordinal scale combining in-hospital death (assigned a value of -1) and days free of organ support to day 21.\nThe trial uses a Bayesian statistical model with predefined criteria for superiority, efficacy, equivalence, or futility.\nAn odds ratio greater than 1 represented improved survival, more organ support-free days, or both.\nBoth tocilizumab and sarilumab met the predefined criteria for efficacy.\nAt that time, 353 patients had been assigned to tocilizumab, 48 to sarilumab, and 402 to control.\nThe median number of organ support-free days was 10 (interquartile range, -1 to 16) in the tocilizumab group, 11 (interquartile range, 0 to 16) in the sarilumab group, and 0 (interquartile range, -1 to 15) in the control group.\nThe median adjusted cumulative odds ratios were 1.64 (95% credible interval, 1.25 to 2.14) for tocilizumab and 1.76 (95% credible interval, 1.17 to 2.91) for sarilumab as compared with control, yielding posterior probabilities of superiority to control of more than 99.9% and of 99.5%, respectively.\nAn analysis of 90-day survival showed improved survival in the pooled interleukin-6 receptor antagonist groups, yielding a hazard ratio for the comparison with the control group of 1.61 (95% credible interval, 1.25 to 2.08) and a posterior probability of superiority of more than 99.9%.\nAll secondary analyses supported efficacy of these interleukin-6 receptor antagonists.\nIn critically ill patients with Covid-19 receiving organ support in ICUs, treatment with the interleukin-6 receptor antagonists tocilizumab and sarilumab improved outcomes, including survival.\n(REMAP-CAP ClinicalTrials.gov number, NCT02735707.).\nCopyright \u00a9 2021 Massachusetts Medical Society.\n", "Evidence Map": {"Enrollment": [{"term": "Critically Ill Patients", "negation": "affirmed", "UMLS": {}, "start": 38, "end": 61}, {"term": "Covid-19", "negation": "affirmed", "UMLS": {}, "start": 67, "end": 75}, {"term": "Adult patients", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 14}, {"term": "Covid-19", "negation": "affirmed", "UMLS": {}, "start": 20, "end": 28}, {"term": "organ support", "negation": "affirmed", "UMLS": {}, "start": 62, "end": 75}, {"term": "critically ill patients", "negation": "affirmed", "UMLS": {}, "start": 3, "end": 26}, {"term": "Covid-19", "negation": "affirmed", "UMLS": {}, "start": 32, "end": 40}, {"term": "organ support", "negation": "affirmed", "UMLS": {}, "start": 51, "end": 64}, {"term": "ICUs", "negation": "affirmed", "UMLS": {}, "start": 68, "end": 72}], "Comparison Results": [], "Study Arm 1 Results": [], "Study Arm 2 Results": [], "Hypothesis": []}, "Sentence-level breakdown": [{"Section": "TITLE", "Text": "Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19 .", "Evidence Elements": {"Participant": [{"term": "Critically Ill Patients", "negation": "affirmed", "UMLS": {}, "start": 38, "end": 61}, {"term": "Covid-19", "negation": "affirmed", "UMLS": {}, "start": 67, "end": 75}], "Intervention": [{"term": "Interleukin-6 Receptor Antagonists", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 34}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "BACKGROUND", "Text": "The efficacy of interleukin-6 receptor antagonists in critically ill patients with coronavirus disease 2019 ( Covid-19 ) is unclear .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "We evaluated tocilizumab and sarilumab in an ongoing international , multifactorial , adaptive platform trial .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "tocilizumab", "negation": "affirmed", "UMLS": {}, "start": 13, "end": 24}, {"term": "sarilumab", "negation": "affirmed", "UMLS": {}, "start": 29, "end": 38}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "Adult patients with Covid-19 , within 24 hours after starting organ support in the intensive care unit ( ICU ) , were randomly assigned to receive tocilizumab ( 8 mg per kilogram of body weight ) , sarilumab ( 400 mg ) , or standard care ( control ) .", "Evidence Elements": {"Participant": [{"term": "Adult patients", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 14}, {"term": "Covid-19", "negation": "affirmed", "UMLS": {}, "start": 20, "end": 28}, {"term": "organ support", "negation": "affirmed", "UMLS": {}, "start": 62, "end": 75}], "Intervention": [{"term": "tocilizumab", "negation": "affirmed", "UMLS": {}, "start": 147, "end": 158}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "The primary outcome was respiratory and cardiovascular organ support-free days , on an ordinal scale combining in-hospital death ( assigned a value of -1 ) and days free of organ support to day 21 .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [{"term": "respiratory and cardiovascular organ support-free days", "negation": "affirmed", "UMLS": {}, "start": 24, "end": 78}, {"term": "in-hospital death", "negation": "affirmed", "UMLS": {}, "start": 111, "end": 128}, {"term": "free of organ support", "negation": "affirmed", "UMLS": {}, "start": 165, "end": 186}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "The trial uses a Bayesian statistical model with predefined criteria for superiority , efficacy , equivalence , or futility .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "An odds ratio greater than 1 represented improved survival , more organ support-free days , or both .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [{"term": "odds ratio", "negation": "negated", "UMLS": {}, "start": 3, "end": 13}, {"term": "survival", "negation": "negated", "UMLS": {}, "start": 50, "end": 58}, {"term": "organ support-free days", "negation": "affirmed", "UMLS": {}, "start": 66, "end": 89}], "Observation": [{"term": "greater than 1", "negation": "negated", "UMLS": {}, "start": 14, "end": 28}, {"term": "improved", "negation": "negated", "UMLS": {}, "start": 41, "end": 49}, {"term": "more", "negation": "negated", "UMLS": {}, "start": 61, "end": 65}], "Count": []}, "Evidence Propositions": []}, {"Section": "RESULTS", "Text": "Both tocilizumab and sarilumab met the predefined criteria for efficacy .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "tocilizumab", "negation": "affirmed", "UMLS": {}, "start": 5, "end": 16}, {"term": "sarilumab", "negation": "affirmed", "UMLS": {}, "start": 21, "end": 30}], "Outcome": [{"term": "efficacy", "negation": "affirmed", "UMLS": {}, "start": 63, "end": 71}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "RESULTS", "Text": "At that time , 353 patients had been assigned to tocilizumab , 48 to sarilumab , and 402 to control .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "tocilizumab", "negation": "affirmed", "UMLS": {}, "start": 49, "end": 60}, {"term": "sarilumab", "negation": "affirmed", "UMLS": {}, "start": 69, "end": 78}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "RESULTS", "Text": "The median number of organ support-free days was 10 ( interquartile range , -1 to 16 ) in the tocilizumab group , 11 ( interquartile range , 0 to 16 ) in the sarilumab group , and 0 ( interquartile range , -1 to 15 ) in the control group .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "tocilizumab", "negation": "affirmed", "UMLS": {}, "start": 94, "end": 105}, {"term": "sarilumab", "negation": "affirmed", "UMLS": {}, "start": 158, "end": 167}], "Outcome": [{"term": "median number of organ support-free days", "negation": "affirmed", "UMLS": {}, "start": 4, "end": 44}], "Observation": [{"term": "10", "negation": "affirmed", "UMLS": {}, "start": 49, "end": 51}, {"term": "11", "negation": "affirmed", "UMLS": {}, "start": 114, "end": 116}, {"term": "0", "negation": "affirmed", "UMLS": {}, "start": 50, "end": 51}], "Count": []}, "Evidence Propositions": [{"Intervention": "tocilizumab", "Observation": "10", "Outcome": "median number of organ support-free days", "Count": ""}, {"Intervention": "sarilumab", "Observation": "11", "Outcome": "median number of organ support-free days", "Count": ""}]}, {"Section": "RESULTS", "Text": "The median adjusted cumulative odds ratios were 1.64 ( 95 % credible interval , 1.25 to 2.14 ) for tocilizumab and 1.76 ( 95 % credible interval , 1.17 to 2.91 ) for sarilumab as compared with control , yielding posterior probabilities of superiority to control of more than 99.9 % and of 99.5 % , respectively .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "tocilizumab", "negation": "affirmed", "UMLS": {}, "start": 99, "end": 110}, {"term": "sarilumab", "negation": "affirmed", "UMLS": {}, "start": 166, "end": 175}, {"term": "control", "negation": "affirmed", "UMLS": {}, "start": 193, "end": 200}], "Outcome": [{"term": "median adjusted cumulative odds ratios", "negation": "affirmed", "UMLS": {}, "start": 4, "end": 42}, {"term": "posterior probabilities of superiority to", "negation": "affirmed", "UMLS": {}, "start": 212, "end": 253}], "Observation": [{"term": "1.64", "negation": "affirmed", "UMLS": {}, "start": 48, "end": 52}, {"term": "1.76", "negation": "affirmed", "UMLS": {}, "start": 115, "end": 119}], "Count": []}, "Evidence Propositions": [{"Intervention": "tocilizumab", "Observation": "1.64", "Outcome": "median adjusted cumulative odds ratios", "Count": ""}, {"Intervention": "control", "Observation": "1.76", "Outcome": "median adjusted cumulative odds ratios", "Count": ""}, {"Intervention": "control", "Observation": "1.76", "Outcome": "posterior probabilities of superiority to", "Count": ""}]}, {"Section": "RESULTS", "Text": "An analysis of 90-day survival showed improved survival in the pooled interleukin-6 receptor antagonist groups , yielding a hazard ratio for the comparison with the control group of 1.61 ( 95 % credible interval , 1.25 to 2.08 ) and a posterior probability of superiority of more than 99.9 % .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "interleukin-6 receptor antagonist", "negation": "affirmed", "UMLS": {}, "start": 70, "end": 103}, {"term": "control", "negation": "affirmed", "UMLS": {}, "start": 165, "end": 172}], "Outcome": [{"term": "90-day survival", "negation": "affirmed", "UMLS": {}, "start": 15, "end": 30}, {"term": "survival", "negation": "affirmed", "UMLS": {}, "start": 22, "end": 30}, {"term": "hazard ratio", "negation": "affirmed", "UMLS": {}, "start": 124, "end": 136}, {"term": "probability of", "negation": "affirmed", "UMLS": {}, "start": 245, "end": 259}], "Observation": [{"term": "improved", "negation": "affirmed", "UMLS": {}, "start": 38, "end": 46}, {"term": "1.61", "negation": "affirmed", "UMLS": {}, "start": 182, "end": 186}], "Count": []}, "Evidence Propositions": [{"Intervention": "control", "Observation": "1.61", "Outcome": "hazard ratio", "Count": ""}]}, {"Section": "RESULTS", "Text": "All secondary analyses supported efficacy of these interleukin-6 receptor antagonists .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "interleukin-6 receptor antagonists", "negation": "affirmed", "UMLS": {}, "start": 51, "end": 85}], "Outcome": [], "Observation": [{"term": "efficacy", "negation": "affirmed", "UMLS": {}, "start": 33, "end": 41}], "Count": []}, "Evidence Propositions": []}, {"Section": "CONCLUSIONS", "Text": "In critically ill patients with Covid-19 receiving organ support in ICUs , treatment with the interleukin-6 receptor antagonists tocilizumab and sarilumab improved outcomes , including survival .", "Evidence Elements": {"Participant": [{"term": "critically ill patients", "negation": "affirmed", "UMLS": {}, "start": 3, "end": 26}, {"term": "Covid-19", "negation": "affirmed", "UMLS": {}, "start": 32, "end": 40}, {"term": "organ support", "negation": "affirmed", "UMLS": {}, "start": 51, "end": 64}, {"term": "ICUs", "negation": "affirmed", "UMLS": {}, "start": 68, "end": 72}], "Intervention": [{"term": "interleukin-6 receptor antagonists tocilizumab", "negation": "affirmed", "UMLS": {}, "start": 94, "end": 140}, {"term": "sarilumab", "negation": "affirmed", "UMLS": {}, "start": 145, "end": 154}], "Outcome": [{"term": "outcomes", "negation": "affirmed", "UMLS": {}, "start": 164, "end": 172}], "Observation": [{"term": "improved", "negation": "affirmed", "UMLS": {}, "start": 155, "end": 163}], "Count": []}, "Evidence Propositions": []}, {"Section": "CONCLUSIONS", "Text": "( REMAP-CAP ClinicalTrials.gov number , NCT02735707 . ) .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "Copyright \u00a9 2021 Massachusetts Medical Society .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}]}